Navigation Links
Neurocrine Biosciences Reports Third Quarter 2009 Results
Date:10/28/2009

placebo and active controlled trial with four treatment arms; elagolix 150 mg, elagolix 250 mg, leuprolide depot, and placebo. We expect top-line data based on the first three months of placebo and active controlled treatment to be available later in the fourth quarter.

An abstract providing Petal Study (0603) clinical efficacy and safety data was presented at the American Society for Reproductive Medicine in Atlanta, on October 21, 2009.

Urocortin 2 Update

The Christchurch Cardioendocrine Research Group at University of Otago, Christchurch School of Medicine and Health Sciences, New Zealand, in collaboration with Neurocrine, has obtained regulatory approval to begin a pilot study in patients with Acute Decompensated Heart Failure. These patients are the target population for the Urocortin 2 mechanism of action and the investigational intervention will be compared to standard-of-care treatment; enrollment of 50 subjects is underway.

VMAT2 Update

The highly selective blockade of the Vesicular Monoamine Transporter 2 (VMAT2) with NBI-98854 should be of clinical benefit in patients with a variety of CNS diseases, especially those with involuntary hyperkinetic movement disorders such as Tardive Dyskinesia. During August 2009, we initiated a single ascending dose Phase 1 study in Canada. Pending successful completion and evaluation of this initial Phase I study, we expect to launch a second Phase I study assessing multiple repeated doses of NBI-98854 in early 2010.

Conference Call and Webcast Thursday, October 29, 2009 at 8:30a.m. EDT

Neurocrine will hold a live conference call and webcast tomorrow morning, Thursday, October 29, 2009 at 8:30 a.m. Eastern Daylight Time (5:30 a.m. Pacific Daylight Time). Participants can access the live conference call by dialing 1-800-894-5910 (US) or 785-424-1052 (International) using the conference passcode 7NEURO. The call can also be ac
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
2. Neurocrine Biosciences Presents Elagolix Data
3. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
6. Neurocrine Biosciences Reports First Quarter 2008 Results
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
8. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
11. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  iMD Companies, Inc. (ICBU) has repositioned itself as ... and grab a foothold in the hydroponic, hemp and medical ... a presence in the sector, and recently partnering with the ... hemp and medical marijuana, iMD is committing to bring its ...
(Date:1/23/2015)... MONMOUTH JUNCTION, N.J. , Jan. 23, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... surgery patients, announced the receipt of $385,642, net ... approved participant of the Technology Business Tax Certificate ...
(Date:1/23/2015)... CHENGDU, China , Jan. 23, 2015 Tianyin ... pharmaceutical company that specializes in the development and sale ... branded generics and active pharmaceutical ingredients (API) today announced ... Facility (JCM) API operation. 1. Following the ...
Breaking Medicine Technology:iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4
... May 10, 2011 Dey Pharma, L.P., a subsidiary of ... recognize the 14th annual Food Allergy Awareness Week (FAAW), May ... in 1997, FAAW aims to educate others and raise awareness ... 25 Americans.(1,2) Food allergies are the most common trigger of ...
... Surgical Information Systems ("SIS") announced today that Huntsville ... solution to automate its perioperative department, interfacing with ... care benefits while increasing revenue and generating significant ... best supports the facility,s goals in automating the ...
Cached Medicine Technology:Dey Pharma Commemorates 14th Annual Food Allergy Awareness Week 2Dey Pharma Commemorates 14th Annual Food Allergy Awareness Week 3Dey Pharma Commemorates 14th Annual Food Allergy Awareness Week 4Dey Pharma Commemorates 14th Annual Food Allergy Awareness Week 5Dey Pharma Commemorates 14th Annual Food Allergy Awareness Week 6Huntsville Memorial Hospital Selects Surgical Information Systems to Increase Safety, Generate Cost Savings 2Huntsville Memorial Hospital Selects Surgical Information Systems to Increase Safety, Generate Cost Savings 3
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 Thousand ... Fresenius Medical Care recalled its GranuFlo and NaturaLyte dialysis ... litigation underway in U.S. District Court, District of Massachusetts, ... January 20th, the Court has remanded a case filed ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... 2015 Payday lending practices in four ... cause financial distress to the states that permit them, ... University’s Center on Race and Wealth. , While they ... payday loans at the same time substantially depress economic ...
(Date:1/22/2015)... a new blog post explaining the importance of keeping a first ... an auto insurance policy . , Clients who driver safer ... vehicle insurance policies. The safety a vehicle offers from its driver ... this, drivers should always carry a first aid kit in their ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... , ... named Capital Confirmation, Inc. its 2010 Best in Business winner for the 1 – 25 ... ... provider of secure audit confirmation services, was named “Best in Business” in the 1 – ...
... ... report assessing best pharmaceutical value-added programs and account managers among key managed care ... ... an ongoing market research project that provides strategic and tactical information to assist ...
... variations might reveal women most at risk, researchers say , ... expression of two common genes trigger cellular changes that can ... researchers adjusted the expression of the genes -- estrogen receptor ... they made in the rodents likely mimic natural variations of ...
... Hundreds ... HCG and how can it help us? , ... May 13, 2010 -- HCG, or human chorionic gonadotropin, is a natural hormone that is found in ... as energy for both the mom and her developing baby. , , , , ,Now, thanks ...
... Non surgical ... ... (GLI) announced a revolutionary hair replication solution recently at their Edina, Mn, office. They utilize ... available. It restores the permanent look of a full head of hair in one day ...
... ... of IT consulting, with many companies providing a variety of high tech services nationwide. ... to offer a spectrum of services to commercial, academic, and governmental IT organizations. , ... South Plainfield, N.J. May 12, 2010 ...
Cached Medicine News:Health News:Capital Confirmation Named Best In Business by Nashville Business Journal 2Health News:Capital Confirmation Named Best In Business by Nashville Business Journal 3Health News:HIRC Research Alert: New Study Identifies Best Pharmaceutical Company Account Managers and Program Offerings 2Health News:HIRC Research Alert: New Study Identifies Best Pharmaceutical Company Account Managers and Program Offerings 3Health News:Small Changes in Two Genes May Trigger Breast Cancer 2Health News:All About the HCG Drops Diet Program—What it is and Why it Works 2Health News:Good Look Ink Announces Revolutionary Hair Replication Solution 2Health News:Astir IT Solutions Inc. Acquires Inothink Solutions 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: